Time in Target Range for Hemoglobin A 1c and Systolic Blood Pressure: Association With Adverse Kidney Events.

Am J Kidney DisJul 17, 2026 (epub)
Clinical ResearchNephrologyEndocrinology

Xi Meng, Yueyue Wang, Xiaoyun Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This observational cohort study analyzed data from 6,542 participants in the ACCORD trial to evaluate the association of time in target range (TTR) for hemoglobin A1c (HbA1c) and systolic blood pressure (SBP) with kidney outcomes in patients with type 2 diabetes and hypertension. A HbA1c-TTR of 100% was linked to a 20% lower risk of adverse kidney events compared to the lowest tertile.

Key findings

  • HbA1c-TTR of 100% was associated with a 20% lower risk of composite kidney outcomes (HR, 0.80).
  • SBP-TTR of 100% was associated with a 32% lower risk of composite kidney outcomes (HR, 0.68).
  • Participants with both HbA1c-TTR and SBP-TTR > 80% had a 29% lower risk of composite kidney outcomes (HR, 0.71).

Why it matters

Understanding the relationship between time in target range for HbA1c and SBP with kidney outcomes can help clinicians optimize management strategies for patients with type 2 diabetes and hypertension, potentially reducing the risk of adverse kidney events.

What to keep in mind

Limited duration of follow-up and low number of kidney failure events.

Source

PubMed · PMID 42468834

Published in Am J Kidney Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.